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INTRODUCTION
Glaucoma, the second leading cause of blindness in the world, requires chronic, life-long treatment with an array of therapeutic options available including medications, laser treatment and surgical implants [1, 2] . The common therapeutic goal of surgical treatment for this progressive and debilitating disease is to lower intraocular pressure (IOP) to target levels to prevent loss of visual field, while enabling patients to recover faster and with fewer complications [2] . An ideal procedure for the treatment of open-angle glaucoma (OAG) would restore physiologic outflow and decrease IOP using a minimally invasive approach.
Limitations and safety considerations of the multitude of therapies has prompted the development of a safer, less invasive treatment for glaucoma designed to prevent the need for trabeculectomy or other invasive procedures associated with significant damage to intraocular and extraocular structures and resulting significant postoperative complications.
The advent of micro-invasive glaucoma surgery (MIGS) using ab interno trabecular micro-bypass stents has been shown to be safe and effective for mild-moderate glaucoma subjects in conjunction with cataract surgery [3] [4] [5] . These stents bypass the trabecular meshwork, which is considered the primary source of resistance to aqueous drainage in many glaucomas, in order to improve outflow through the natural physiologic pathway and reduce IOP [3, [6] [7] [8] . MIGS has the potential to preserve important eye tissue and future treatment options that may help maintain long-term vision for the patient with glaucoma [9] . The first generation iStent Tonometers were calibrated monthly.
Subjects selected for the trial began a washout of all glaucoma medications (4 weeks for prostaglandin analogs and beta-blockers, 2 weeks for alpha adrenergic agonists and carbonic anhydrase inhibitors). At baseline, the subjects' BCVA (via Early Treatment of Diabetic Retinopathy Study system [15] ), cupto-disc ratio (C:D), central corneal thickness and IOP were measured. Un-medicated diurnal IOP measurements were taken at selected sites at 8 am, 10 am, 12 pm, and 4 pm (±1 h).
iStent Inject Device
The micro-bypass iStent inject device GTS400 is a single-piece, heparin-coated, gamma-sterilized device made from implant-grade titanium. The one-piece device is 360 lm in length, and the maximal width of the conical head is 230 lm.
The stent is symmetrically designed such that it may be used in either the right or left eye. The iStent inject is smaller than the first generation iStent, but functions in the same way to bypass the trabecular meshwork to improve aqueous flow from the anterior chamber into Schlemm's canal. The iStent inject devices are pre-loaded in the customized injector system designed to deliver the stents automatically into Schlemm's canal through a stainless steel insertion tube. The injector features a surgeonactivated release button on the housing, which is pressed to allow the stent to move over a small guiding trocar to exit the injector. The G2-0 injector housed one stent; therefore, two injectors were used during implantation. The G2-M-IS system houses two stents, thereby enabling insertion of both stents from one injector. A diagram of the iStent inject is presented in Fig. 1 .
Surgery and Follow-up
Two iStent inject devices were implanted through the trabecular meshwork into Schlemm's canal at the nasal position, separated by approximately two clock hours,
Fig. 1 Trabecular Micro-Bypass Stent Model GTS400
using topical anesthesia and stent insertion methods similar to those described previously [16] . Following implantation of two iStents, subjects received topical postoperative antiinflammatory and anti-infective medications for 4 weeks. The study protocol further indicated that if at any time during the study, a subject's IOP exceeded 38 mmHg, the subject would be exited from the study and alternative treatment commenced at the discretion of the investigator.
Study Endpoints and Statistical Analysis
The primary efficacy endpoint was defined as the proportion of subjects with IOP of The subject population in this trial included qualified subjects who underwent implantation of two GTS-400 iStent inject devices with either insertion device, the G2-0 injector or the G2-M-IS system. The safety and efficacy data comprise all study subjects (regardless of insertion device) because the implanted stents are identical in all cases. For the primary and secondary efficacy endpoints, proportional analyses were performed. Exact 95% confidence intervals based on a binomial distribution were calculated for the responder rates. For continuous variables such as mean IOP and IOP reduction, 95% confidence intervals were computed using the t-distribution. Statistical tests were performed using PC-SAS software (version 9.1.3, SAS Institute Inc., Cary, NC, USA).
RESULTS

Subject Disposition and Demographics
A total of 112 subjects were enrolled in the study. One subject did not have baseline information recorded and eight subjects did not have at least two medications at screening.
Four enrolled subjects did not undergo implantation of two devices. These 13 subjects 
Intraocular Pressure and Medication Use
The primary endpoint, IOP B 18 mmHg at 12 months without medications, was achieved by 66% of subjects (n = 58 of 88 eyes; 95% CI 55%, 76%; Table 3 ). The secondary endpoint, IOP B 18 mmHg at 12 months regardless of medications was achieved by 81% of subjects (n = 71 of 88 eyes; 95% CI 71%, 88%), of which 12 subjects were using a prostaglandin at Month 12. Furthermore, 72% of subjects (n = 63, 95% CI 61%, 81%) experienced a 20% or greater reduction in IOP without medication at 12 months, 93% (n = 82, 95% CI 86%, 97%) experienced a 20% or greater reduction in IOP regardless of medication at 12 months, and 77% Best Corrected Visual Acuity, Slit-Lamp,
Pachymetry
The proportion of subjects with BCVA of 20/40 or better was 84% at screening, 84% at 1 and 3 months, 88% at 6 months and 86% at 12 months (Table 5 ). The mean C:D ratio at Month 12 was 0.7 ± 0.2, and did not change IOP intraocular pressure, SSI secondary surgical intervention a Diurnal IOP was taken for the visit at selected sites b SSI related to glaucoma. Outcomes after SSI were excluded
Postoperative Adverse Events and Other Observations
Eighteen ocular adverse events were reported ( Table 6 ). Ten of these adverse events were elevated IOP. Elevated IOP resolved in four subjects after treatment with medication, and in six subjects after surgical intervention, including two trabeculectomies and one increased facility-of-outflow and to achieve further reductions in IOP. Work by Belovay et al. [17] showed the benefit of multiple implantation of stents in conjunction with cataract surgery to reduce mean IOP to less than 15 mmHg while also reducing medication burden through a period of 12 months postoperative. An initial study demonstrated that subjects with mild-to-moderate OAG who were implanted with two iStent devices as a sole procedure reported an average IOP of 13.6 mmHg at 1 year postoperatively without the need for ocular hypotensive medication [18, 19] . Further, this study confirmed that IOP reduction to \15 mmHg and elimination of medication burden is possible after implantation of two iStent devices, as a standalone procedure, without significant postoperative adverse effects. The study concluded MIGS with iStent to be a safe and effective implant procedure that supports earlier intervention in mild-to-moderate OAG [18, 19] . Thus, multiple stent usage has been shown to be viable, both in a theoretical in vitro perfusion model [14, 15] and in clinical experience [18, 19] . Baseline last available measurement before implantation, BCVA best corrected visual acuity
The current post-market, prospective, multicenter study evaluated the safety and IOPlowering efficacy of two GTS-400 iStent inject devices implanted as a sole procedure. The study comprised 99 subjects who underwent implantation of two iStent devices per eye with either the G2-0 injectors or the G2-M-IS injector and were followed for 1 year. To our knowledge, this is the first prospective multi-centered study of iStent inject implantation as the sole procedure in eyes with open-angle glaucoma.
The merits of the data include, among other factors, a high rate of subject follow-up through 1 year (93%; n = 92/99).
This study in subjects with OAG on two or more preoperative medications showed mean IOP reduction through 1 year. Most subjects reported IOP B 18 mmHg without the use of concomitant medication.
With IOP reduction C 30% in 61% of subjects without medication and in 77% of subjects regardless of medication, it is shown that the Preferred Practice Pattern goal Ò of 25% IOP reduction from pre-treatment baseline [2] was achieved in the majority of subjects in this study. The medication reduction from preoperative use was noteworthy. Furthermore, the IOPlowering effect of two iStent inject devices implanted as a sole procedure in this study appears to be greater than that of a single iStent implanted in conjunction with cataract surgery.
The iStent US pivotal trial of iStent found that 66% of treatment eyes versus 48% of control eyes achieved C20% IOP reduction without medication at Month 12 (P = 0.003) [3] .
Results from the current study compare favorably: 72% achieved C20% IOP reduction without medication at Month 12, and 93% the Month 12 IOP reduction of 20% or more regardless of medication. 
